Volume 4, 2020

Biochemistry

FREE FATTY ACIDS AND HEPATIC ACTIVITY IN TYPE 2 DIABETES

Šaćira Mandal

Pages: 90-94

DOI: 10.21175/RadProc.2020.19

Metabolic derangements in Type 2 diabetes mellitus (T2D) are associated primarily with the carbohydrate and lipid levels disturbances. Increased flow of free fatty acids (FFAs) into the blood that is coming from the adipocytes as well as an elevated flux of FFAs from de novo lipid synthesis in the liver contribute to these metabolic disturbances. Previous studies suggested a strong association of the hepatic activity of certain enzymes, such as aspartate and alanine transferase (AST, ALT), gamma glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP) with the progression of T2D. In this study, the potential association of the hepatic activities of the liver enzymes and FFAs levels in T2D was examined. Analysis of the activities of ALT, AST, GGT and AP, as well levels of FFAs, fasting plasma glucose (FPG), and lipid profile was performed in 40 healthy control and 71 diabetic subjects. All participants were free of hepatitis, viral infections or active liver damage. The results showed a positive association between levels of palmitic and oleic acids with ALT activity (p<0.05), while the activity of GGT was significantly associated with the levels of palmitic, stearic, and oleic fatty acids (p<0.01). Interestingly, in control group, a positive correlation was found between palmitoleic acid levels with ALT activity (p<0.05), and a negative correlation palmitoleic acid with ALP activity (p<0.05) was observed. Obtained data suggest that an elevation of free fatty acid levels and the hepatic fat accumulation in insulin-resistant conditions affect the hepatic enzymes activities, which might contribute further to the progression of Type 2 diabetes and its complications.
  1. IDF. International Diabetes Federation. IDF Diabetes Atlas — 9th Edition. Diabetes Atlas.
    Retrieved from: https://diabetesatlas.org/resources/2017-atlas.html
    Retrieved on: Sep. 17, 2020
  2. P. J. Randle, P. B. Garland, C. N. Hales, E. A. Newsholme, “The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus,” Lancet, vol. 281, no. 7285, pp. 785 –789, Apr. 1963.
    DOI: 10.1016/s0140-6736(63)91500-9
    PMid: 13990765
  3. M. Hawkins, J. Tonelli, P. Kishore, D. Stein, E. Ragucci, A. Gitig, K. Reddy, “Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes,” Diabetes, vol. 52, no. 11, pp. 2748 – 2758, Nov. 2003.
    DOI: 10.2337/diabetes.52.11.2748
    PMid: 14578293
  4. J. A. Menendez, A. Vazquez-Martin, F. Jose Ortega, J. M. Fernandez-Real, “Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer,” Clin. Chem., vol. 55, no. 3, pp. 425 – 438, Jan. 2009.
    DOI: 10.1373/clinchem.2008.115352
    PMid: 19181734
  5. S. Jiang, J. L. Young, K. Wang, Y. Qian, L. Cai, “Diabetic induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus,” Mol. Med. Rep., vol. 22, no.2, pp. 603 –611, Aug. 2020.
    DOI: 10.3892/mmr.2020.11175
    PMid: 32468027
  6. J. Zhang, N. Cheng, Y. Ma, H. Li, Z. Cheng, Y. Yang, et al., “Liver enzymes, fatty liver and type 2 diabetes mellitus in a Jinchang cohort: a prospective study in adults,” Can. J. Diabetes, vol. 42, no. 6, pp. 652–658, Dec. 2018.
    DOI: 10.1016/j.jcjd.2018.02.002
    PMid: 29936075
  7. S. Nagaraj, S. S. Kiran, R. Gandham, W. D. C. R. Silvia, M. R. Nagaraja, A. S.Nasar, D. Biswajit, “Study of prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients and variations in liver function tests, lipid profile and mean platelet volume in patients with fatty liver in comparison with patients without fatty liver,” Int. J. Res. Med. Sci., vol. 4, no. 3, pp. 871– 876, Mar. 2016.
    DOI: 10.18203/2320-6012.ijrms20160534
    PMid: 603
  8. X.-Y. Hu, Y. Li, L.-Q. Li, Y. Zheng, J.-H. Lv, S.-C. Huang, W. Zhang, L. Liu, L. Zhao, Z. Liu, X.-J. Zhao, “Risk factors and biomarkers of nonalcoholic fatty liver disease: an observational cross-sectional population survey,” BMJ Open, vol. 8, no. 4, pp. 1 – 7, Apr. 2018.
    DOI: 10.3978/j.issn.2304-3881.2015.01.03
    PMid: 29626047
  9. H. B. Bhatt, R. J. Smith, “Fatty liver disease in diabetes mellitus,” HepatoBiliary Surg. Nutr., vol. 4, no. 2, pp. 101 – 108, Apr. 2015.
    DOI: 10.2337/diabetes.52.11.2748
    PMid: 26005676
  10. F. Bril, K. Cusi, “Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action,” Diabetes Care, vol. 40, no. 3, pp. 419 – 430, Mar. 2017.
    DOI: 10.2337/dc16-1787
    PMid: 28223446
  11. K.L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, E. J. Parks, “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease,” J. Clin. Invest., vol. 115, no. 5, pp. 1343 – 1351, May 2005.
    DOI: 10.1172/JCI23621
    PMid: 15864352
  12. S. Islam, S. Rahman, T. Haque, A. H. Sumon, A. M. Ahmed, N. Ali, “Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross-sectional study in Bangladeshi adults,” Endocrinol. Diabetes Metab., vol. 3, no.2, e00116, Apr. 2020.
    DOI: 10.1002/edm2.116
    PMid: 32318634
  13. D. M. Tanase, E. M. Gosav, C. F. Costea, M. Ciocoiu, C. M. Lacatusu, M. A. Maranduca, A. Ouatu, M. Floria, “The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)”, Journal of Diabetes Research, vol. 2020, Article ID 3920196, p. 16, Aug. 2020.
    DOI: 10.1155/2020/3920196
    PMid: 343446834
  14. M. T. Long, S. Gandhi, R. Loomba, “Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease”, Metabolism, vol. 111, pp. 154259-1-8, Oct. 2020.
    DOI: 10.1016/j.metabol.2020.154259
    PMid: 32387227
  15. Association AD. 4, Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019, Diabetes Care, vol. 42 (Suppl 1), pp. S34-S45, 2019.
    DOI: 10.2337/dc19-S004
  16. American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018, Diabetes Care, vol. 41 (Suppl 1), pp. S13-S27, 2018.
  17. Ethical principles for medical research involving Human Subjects , World Medical Association, Helsinki, Finland, 1964.
    Retrieved from: https://www.who.int/bulletin/archives/79(4)373.pdf
    Retrieved on: Sep. 17, 2020
  18. R. Feng, C. Luo, C. Li, S. Du, A. P. Okekunle, Y. Li, Y. Chen, T. Zi, Y. Niu, “Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case – control study,” Lipids in Health and Disease, vol. 16, no. 165, pp. 1-9, Sep. 2017.
    DOI: 10.1186/s12944-017-0551-1
    PMid: 28870233
  19. T. Shibabaw, G. Dessie, M. D. Molla, M. F. Zerihun, B. Ayelign, “Assessment of liver marker enzymes and its association with type 2 diabetes mellitus in Northwest Ethiopia,” BMC. Res. Notes., vol. 12, no. 707, pp. 1– 5, Oct. 2019.
    DOI: 10.1186/s13104-019-4742-x
    PMid: 204940234
  20. F. Imamura, A. M. Fretts, M. Marklund, A. V. Ardisson Korat, W.-S. Yang, M. Lankinen, et al., “Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies,” PLoS Med., vol. 17, no. 6, pp. e1003102–1-7, Jun. 2020.
    DOI: 10.1371/journal. pmed.1003102
    PMid: 32530938
  21. T. K. Lam, A. Carpentier, G. F. Lewis, G. van de Werve, I. G. Fantus, A. Giacca, “Mechanisms of the free fatty acid-induced increase in hepatic glucose production,” Am. J. Physiol. Endocrino. Metab., vol. 284, no. 5, pp. E863–73. May 2003.
    DOI: 10.1152/ajpendo.00033.2003
    PMid: 12676648
  22. H. R. Ahn, M. H. Shin, H. S. Nam, K.-S. Park, Y.–H. Lee, S.-K. Jeong, “The association between liver enzymes and risk of type 2 diabetes: The Namwon study,” Diabetol. Metab. Syndr., vol. 6, no. 1, p. 14, Feb. 2014.
    DOI: 10.1186/1758-5996-6-14
    PMid: 24502834
  23. S.-H. Ko, M. K. Baeg, K.-D. Han, S.-H. Ko, Y.-B. Ahn, “Increased liver markers are associated with higher risk of type 2 diabetes,” World J. Gastroenterol., vol. 21, no. 24, pp. 7478–87, June 2015.
    DOI: 10.3748/wjg.v21.i24.7478
    PMid: 26139993
  24. S. Tomah, N. Alkhouri, O Hamdy, “Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?”, Clin. Diabetes Endocrinol., vol. 6, no. 9, pp. 1–12, June 2020.
    DOI: 10.1186/s40842-020-00097-1
    PMid: 32518675
  25. M. Akheruzzaman, V. Hegde, A. C. Shin, N. V. Dhurandhar, “Reducing endogenous insulin is linked with protection against hepatic steatosis in mice,” Nutr. Diabetes, vol. 10, no. 1, pp. 1–12, Apr. 2020.
    DOI: 10.1038/s41387-020-0114-9
    PMid: 32286259
Šaćira Mandal, "Free fatty acids and hepatic activity in type 2 diabetes," RAD Conf. Proc, vol. 4, 2020, pp. 90–94, http://doi.org/10.21175/RadProc.2020.19